Biohaven (NYSE:BHVN – Get Free Report) had its price objective dropped by investment analysts at JPMorgan Chase & Co. from $27.00 to $24.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of […]
Biohaven Ltd. (NYSE:BHVN – Get Rating) was the recipient of a significant drop in short interest during the month of April. As of April 15th, there was short interest totalling 6,670,000 shares, a drop of 5.5% from the March 31st total of 7,060,000 shares. Approximately 11.5% of the company’s shares are short sold. Based on […]
Biohaven Ltd. (NYSE:BHVN – Get Rating) – Equities research analysts at Cantor Fitzgerald issued their FY2023 earnings per share (EPS) estimates for shares of Biohaven in a report issued on Tuesday, April 4th. Cantor Fitzgerald analyst C. Duncan anticipates that the company will earn ($4.92) per share for the year. Cantor Fitzgerald currently has a […]
Biohaven Ltd. (NYSE:BHVN – Get Rating) was the recipient of a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 5,940,000 shares, a decrease of 7.2% from the February 28th total of 6,400,000 shares. Based on an average daily trading volume, of 996,300 shares, the […]
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Tuesday, Zacks.com reports. According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat […]